Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Product
Deals
Articles
BioCentury
|
Apr 11, 2016
Company News
Gyros, Protein Technologies deal
...biotherapeutics. Gyros’ products include its Gyrolab xP workstation. Protein’s products include its Symphony X and
Sonata
...
Read More
BioCentury
|
Oct 19, 2015
Company News
Alexza drug delivery, neurology news
...is alprazolam, a GABA receptor modulating benzodiazepine, delivered via the Staccato system inhaler. AZ-007 is
zaleplon
...
Read More
BioCentury
|
May 5, 2014
Clinical News
Lifitegrast: Phase III data
...Top-line data from the double-blind, placebo-controlled, U.S. Phase III
SONATA
safety trial in 332 patients with...
Read More
BioCentury
|
Apr 7, 2014
Finance
1Q Stock Wrap-Up: Small but mighty
...III data 2Q14 Shire plc (LSE:SHP; NASDAQ:SHPG) Lifitegrast Dry eye disease (keratoconjunctivitis sicca) Ph III
SONATA
...
Read More
BioCentury
|
Dec 9, 2013
Clinical News
Lifitegrast: Phase III data
...The company is also evaluating the long-term safety of lifitegrast in the 1-year Phase III
SONATA
...
Read More
BioCentury
|
Apr 1, 2013
Company News
SARcode, Shire deal
...days. The company is also evaluating the long-term safety of lifitegrast in the Phase III
SONATA
...
...to FDA for lifitegrast to treat dry eye disease in 2H14 and that data from
SONATA
...
Read More
BioCentury
|
Jan 14, 2013
Clinical News
Lifitegrast: Phase III started
...The company is also evaluating the long-term safety of lifitegrast in the 1-year Phase III
SONATA
...
Read More
BioCentury
|
Oct 29, 2012
Clinical News
Lifitegrast: Phase III data
...The company is also evaluating the long-term safety of lifitegrast in the 1-year Phase III
SONATA
...
Read More
BioCentury
|
Oct 24, 2012
Clinical News
SARcode reports Phase III data for dry eye treatment
...The company is also evaluating the long-term safety of lifitegrast in the 1-year Phase III
SONATA
...
Read More
BioCentury
|
Jun 20, 2011
Clinical News
SKP-1041: Phase II data
...Inc. , Bedminster, N.J. Product: SKP-1041 Business: Neurology Molecular target: NA Description: Delayed-release formulation of
zaleplon
...
Read More
Items per page:
10
1 - 10 of 51
Previous page
Next page